S
Sequel Pharmaceuticals
Sequel Pharmaceuticals develops and commercializes novel and clinical-stage drug candidates for patients with cardiovascular disease
About Sequel Pharmaceuticals
Sequel Pharmaceuticals (India) Private Limited is a non-government company operating in the manufacturing sector, specifically focusing on metals, chemicals, and related products. Incorporated on June 28, 2006, in Mumbai, Maharashtra, the company has established its presence in the market over the past several years. Initially known as Sequel Pharmachem Private Limited, the firm functions as a private limited company limited by shares.
The company's core business involves the manufacturing and export of active pharmaceutical ingredients (APIs) and their intermediates. It operates with an authorized capital of ₹6.00 crore and a paid-up capital of ₹5.80 crore. The business primarily serves other entities within the pharmaceutical industry that require chemical components for their own manufacturing and drug formulation processes. The company is registered in Mumbai, with its physical location at Ambernath MIDC, Thane.
The leadership of Sequel Pharmaceuticals (India) includes its current board of directors, Nandadip Sakharam Rasam and Ramchandra Haridas Parade. Corporate records indicate the company is active, with its last Annual General Meeting (AGM) held on December 30, 2023, and its most recent balance sheet filed for the fiscal year ending March 31, 2023.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- Parsippany-Troy Hills, United States
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 23.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBT✓Debt | Dec 2010 | $1M | — | Undisclosed | — |
| DEBT✓Debt | Sep 2010 | $1.4M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Sequel Pharmaceuticals is 1.4K monthly website visits, up 180% over the last three months. Sequel Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Skyline Ventures- MPMontreux Equity Partners
InterWest Partners
Domain Associates- FVForward Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sequel Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sequel Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.